Figure 6.

The effect of pGag codelivery during therapeutic anti-ovalbumin (OVA) immunization on the antitumor activity. (a) Experimental plan. C57BL/6 mice were challenged with B16F10-OVA cells. Two days later, they were immunized in a regimen of one prime and two boosts at a 1-week interval with the antigenic OVA plasmid combined or not with HIV-1 Gag plasmid. Tumor growth and mouse survival were assessed after challenge. (b) Survival rates monitoring after challenge. The asterisks indicate significant differences compared with naive mice (*P < 0.05) (comparison of survival curves, Mantel–Cox test). (c) Tumor growth follow-up after challenge in mice immunized with pOVA and pOVA combined with pGag. The results are expressed as mean − SEM (n = 10). The asterisks show significant differences between groups (*P < 0.05) (analysis of variance, Dunnett's post-hoc test).